This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches
by Sridatri Sarkar
TEM expands its precision medicine arsenal with AI-powered tools, liquid biopsy tech and genome sequencing.
Should You Hold Myriad Genetics Stock in Your Portfolio Right Now?
by Zacks Equity Research
MYGN sees growth in oncology and women's health testing, but GeneSight coverage loss clouds the near-term outlook.
Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape?
by Moumi Mondal
TEM's rapid growth and cost discipline are paving the way for a positive adjusted EBITDA in 2025.
Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround
by Zacks Equity Research
Myriad (MYGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook
by Zacks Equity Research
Myriad Genetics delivers a narrower-than-expected loss in the first quarter of 2025.
Myriad (MYGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Myriad (MYGN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 40% and 2.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?
by Moumi Mondal
Both HOLX and Myriad Genetics are longstanding key players in the Molecular Diagnostics space. But which one is a better investment now?
Is Myriad Genetics Stock Worth Holding in Your Portfolio Now?
by Zacks Equity Research
Strategic progress and solid potential in oncology testing keep MYGN on investors' radar.
Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MYGN Q4 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down
by Zacks Equity Research
Myriad Genetics achieves strong revenue growth in the fourth quarter of 2024.
Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Myriad Genetics (MYGN) Meets Q4 Earnings Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 0% and 0.22%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
MYGN Stock Might Rise on Collaboration With CancerCARE
by Zacks Equity Research
Myriad Genetics entered into an agreement with CancerCARE for Life to provide individuals within the latter's network with access to the MyRisk Hereditary Cancer Test.
MYGN Stock Gains Following the Launch of Know More Sooner
by Zacks Equity Research
Myriad Genetics launches an online prenatal genetic testing resource, the Know More Sooner website, to provide comprehensive information about reproductive and prenatal genetic testing.
MYGN Stock Gains Following Collaboration With Hannah Storm
by Zacks Equity Research
Myriad Genetics enters into an agreement with Hannah Storm, who will be the Myriad Genetics Breast Cancer Risk Assessment Program ambassador.
Tempus AI Stock Plunges 28.9% in Three Months: What's Next?
by Debanjana Dey
TEM is enhancing its offerings and expanding the breadth of products and services to improve patient care. However, macro challenges are likely to hurt its performance.
MYGN Stock Might Gain From the New Recognition of RiskScore Study
by Zacks Equity Research
The American Journal of Human Genetics names Myriad Genetics' RiskScore study as one of the top 10 significant advances in genomic medicine.
Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?
by Zacks Equity Research
Strategic progress and solid potential in oncology testing keep MYGN on investors' radar.
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain?
by Zacks Equity Research
Myriad Genetics' Prolaris test reinforced as an 'Advanced Tool' by the NCCN for prognostic assessment.
MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 v2
by Zacks Equity Research
Myriad Genetics incorporates its proprietary HRD platform in Illumina's updated TruSight Oncology 500 v2 comprehensive gene panel assay.
MYGN Stock Might Gain From SneakPeek Availability in Retail Stores
by Zacks Equity Research
Myriad Genetics announces the availability of SneakPeek - the first at-home early fetal sex test in Walmart, Walgreens and CVS stores nationwide.
MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View
by Zacks Equity Research
Myriad Genetics delivers strong third-quarter results, driven by growth within Pharmacogenomics and Prenatal. The company increases its full-year EPS guidance.
Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.